Ceska R, Freiberger T, Vaclova M, Aleksicova T, Votavova L, Vrablik M
Centre for Preventive Cardiology, Third Department of Internal Medicine, University General Hospital and the First Faculty of Medicine, Prague, Czech Republic.
Physiol Res. 2017 Apr 5;66(Suppl 1):S85-S90. doi: 10.33549/physiolres.933599.
This article describes the evolution of our understanding of familial hypercholesterolemia (FH) in the Central, Eastern, and Southern Europe (CESE) region, and the dissemination of this understanding to other countries. Using the ScreenPro FH project as an example, we would like to illustrate the progression from national objectives, to regional networking and, finally, to international collaboration via the Familial Hypercholesterolemia Studies Collaboration (FHSC) project under the leadership of the European Atherosclerosis Society (EAS). It is essential to improve our ability to diagnose FH. In this regard, the EAS and its FHSC project must be commended for their educational and organizational activities which, above all, are dedicated to the creation of a global FH patient registry. In the CESE region, FH diagnostics and treatment situation are markedly different than in Western Europe or North America. Since the Czech MedPed project (Make Early Diagnoses to Prevent Early Deaths in Medical Pedigrees) has been so successful (with results not only comparable to, but, for some parameters, even surpassing the results of many Western countries) we decided to apply the Czech experience to the CESE region. Thus, the ScreenPro FH project was created. The aim of ScreenPro FH is to create a specialist network in the CESE region. The primary objective of the ScreenPro FH project was to dramatically reduce the number of premature deaths due to clinical complications of atherosclerosis in FH patients. At present, ScreenPro FH comprises 18 member countries with a total population of 500,000,000; which, in terms of the FH population, represents 1-2 million patients.
本文描述了我们对中欧、东欧和南欧（CESE）地区家族性高胆固醇血症（FH）认识的演变，以及这种认识向其他国家的传播。以ScreenPro FH项目为例，我们想说明从国家目标到区域网络，最终通过欧洲动脉粥样硬化学会（EAS）领导的家族性高胆固醇血症研究协作（FHSC）项目进行国际合作的进展。提高我们诊断FH的能力至关重要。在这方面，EAS及其FHSC项目的教育和组织活动值得称赞，这些活动首先致力于创建一个全球FH患者登记册。在CESE地区，FH的诊断和治疗情况与西欧或北美明显不同。由于捷克MedPed项目（在医学谱系中进行早期诊断以预防早期死亡）非常成功（其结果不仅与许多西方国家相当，而且在某些参数上甚至超过了它们），我们决定将捷克的经验应用于CESE地区。因此，创建了ScreenPro FH项目。ScreenPro FH的目标是在CESE地区建立一个专家网络。ScreenPro FH项目的主要目标是大幅减少FH患者因动脉粥样硬化临床并发症导致的过早死亡人数。目前，ScreenPro FH包括18个成员国，总人口达5亿；就FH人群而言，代表100万至200万患者。
